CU20170094A7 - Derivados de 4h-pirrol[3,2-c]piridin-4-0na - Google Patents

Derivados de 4h-pirrol[3,2-c]piridin-4-0na

Info

Publication number
CU20170094A7
CU20170094A7 CUP2017000094A CU20170094A CU20170094A7 CU 20170094 A7 CU20170094 A7 CU 20170094A7 CU P2017000094 A CUP2017000094 A CU P2017000094A CU 20170094 A CU20170094 A CU 20170094A CU 20170094 A7 CU20170094 A7 CU 20170094A7
Authority
CU
Cuba
Prior art keywords
compounds
diseases
pirrol
piridin
derivatives
Prior art date
Application number
CUP2017000094A
Other languages
English (en)
Spanish (es)
Inventor
Dr József Bálint
Dr Hans Briem
Dr Keith Graham
Dr Ulrich Klar
Dr Philip Lienau
Dr Volker Schulze
Dr Gerhard Siemeister
René Tempel
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CU20170094A7 publication Critical patent/CU20170094A7/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/45Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
CUP2017000094A 2015-01-28 2016-01-25 Derivados de 4h-pirrol[3,2-c]piridin-4-0na CU20170094A7 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15152944 2015-01-28
EP15200407 2015-12-16
PCT/EP2016/051432 WO2016120196A1 (en) 2015-01-28 2016-01-25 4h-pyrrolo[3,2-c]pyridin-4-one derivatives

Publications (1)

Publication Number Publication Date
CU20170094A7 true CU20170094A7 (es) 2017-12-08

Family

ID=55236350

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2017000094A CU20170094A7 (es) 2015-01-28 2016-01-25 Derivados de 4h-pirrol[3,2-c]piridin-4-0na

Country Status (31)

Country Link
US (1) US10428063B2 (xx)
EP (1) EP3250567B1 (xx)
JP (1) JP6704398B2 (xx)
KR (1) KR102544847B1 (xx)
CN (1) CN107406417B (xx)
AU (1) AU2016212230B2 (xx)
BR (1) BR112017016193B1 (xx)
CA (1) CA2974853C (xx)
CL (1) CL2017001930A1 (xx)
CO (1) CO2017007663A2 (xx)
CR (1) CR20170345A (xx)
CU (1) CU20170094A7 (xx)
DO (1) DOP2017000176A (xx)
EA (1) EA032530B1 (xx)
EC (1) ECSP17048527A (xx)
HK (1) HK1244804A1 (xx)
IL (1) IL253284B (xx)
JO (1) JO3706B1 (xx)
MX (1) MX2017009831A (xx)
MY (1) MY182181A (xx)
NI (1) NI201700096A (xx)
PE (1) PE20171240A1 (xx)
PH (1) PH12017501340A1 (xx)
SG (1) SG11201705908VA (xx)
SV (1) SV2017005487A (xx)
TN (1) TN2017000329A1 (xx)
TW (1) TWI699359B (xx)
UA (1) UA122221C2 (xx)
UY (1) UY36544A (xx)
WO (1) WO2016120196A1 (xx)
ZA (1) ZA201705802B (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR100886A1 (es) 2014-06-17 2016-11-09 Bayer Pharma AG 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
EP3310775B1 (en) 2015-06-17 2020-04-01 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
CN107921286A (zh) 2015-08-05 2018-04-17 拜耳制药股份公司 1h‑吡咯‑3‑胺类化合物
PE20220507A1 (es) 2015-12-16 2022-04-07 Loxo Oncology Inc Compuestos utiles como inhibidores de cinasa
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors
KR102440006B1 (ko) 2017-08-23 2022-09-05 현대모비스 주식회사 차량용 브레이크의 캘리퍼 장치
US11339157B1 (en) 2017-10-24 2022-05-24 Bayer Aktiengesellschaft 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
US20230046077A1 (en) 2019-02-07 2023-02-16 Bayer Aktiengesellschaft 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors
EP3958865A1 (en) 2019-04-24 2022-03-02 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
KR20220004103A (ko) * 2019-04-24 2022-01-11 바이엘 악티엔게젤샤프트 4H-피롤로[3,2-c]피리딘-4-온 화합물
WO2020216773A1 (en) 2019-04-24 2020-10-29 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one compounds
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
EP4188929A1 (en) 2020-07-29 2023-06-07 Bayer Aktiengesellschaft Substituted pyrrolo-pyridinone derivatives and therapeutic uses thereof
EP4188928A1 (en) 2020-07-29 2023-06-07 Bayer Aktiengesellschaft Substituted 1 h-pyrrolo[3,2-b]pyridin compounds and methods of use thereof
TW202220987A (zh) 2020-07-29 2022-06-01 德商拜耳廠股份有限公司 經取代雜環化合物及其治療用途
EP4188551A1 (en) 2020-07-29 2023-06-07 Bayer Aktiengesellschaft Aryl substituted pyrrolo-pyridinones and therapeutic uses thereof
CN115836070A (zh) * 2020-08-10 2023-03-21 上海和誉生物医药科技有限公司 作为egfr抑制剂的稠环化合物及其制备方法和应用
IL301532A (en) 2020-09-23 2023-05-01 Scorpion Therapeutics Inc History Pyrrolo[2,3-C]pyridin-4-one is useful in cancer treatment
WO2022072645A2 (en) * 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022094271A1 (en) * 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) * 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
WO2023147015A1 (en) * 2022-01-27 2023-08-03 The Broad Institute, Inc. Substituted heterocyclic csnk1 inhibitors
WO2023183601A1 (en) 2022-03-24 2023-09-28 Scorpion Therapeutics, Inc. Methods of synthesizing egfr inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966781A (en) 1970-12-17 1976-06-29 Merck Sharp & Dohme (I.A.) Corporation Deuteration of functional group-containing hydrocarbons
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
AR056560A1 (es) 2005-10-06 2007-10-10 Astrazeneca Ab Pirrolopiridinonas como moduladores cb1
US20070142414A1 (en) 2005-12-16 2007-06-21 Pharmacia Italia S.P.A. N-substituted pyrrolopyridinones active as kinase inhibitors
EP2203442B1 (en) 2007-09-28 2012-06-20 Nerviano Medical Sciences S.r.l. Substituted pyrrolo-pyrimidine derivatives, process for their preparation and their use as kinase inhibitors
EP2294065B1 (en) * 2008-01-22 2014-03-19 Vernalis (R&D) Ltd. Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity
ES2570756T3 (es) 2009-06-15 2016-05-20 Nerviano Medical Sciences Srl Derivados pirimidinilpirrolopiridinona sustituidos, proceso para su preparación y su uso como inhibidores de cinasa
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
ES2660265T3 (es) * 2011-10-07 2018-03-21 Nerviano Medical Sciences S.R.L. Derivados de 3,4-dihidropirrolo[1,2-a]pirazin-1(2h)-ona 4-alquil-sustituidos como inhibidores de cinasa
US20140315889A1 (en) 2011-10-28 2014-10-23 Chong Kun Dang Pharmaceutical Corp. Hydroxamate derivatives for hdac inhibitor, and the pharmaceutical composition comprising thereof
ES2638144T3 (es) 2011-12-21 2017-10-18 Bayer Intellectual Property Gmbh Bencilpirazoles sustituidos
WO2013167698A1 (en) 2012-05-11 2013-11-14 Bayer Pharma Aktiengesellschaft Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer
WO2014022752A1 (en) 2012-08-03 2014-02-06 Amgen Inc. Macrocycles as pim inhibitors
CN104870446B (zh) 2012-11-07 2019-08-13 内尔维阿诺医学科学有限公司 取代的嘧啶基和吡啶基吡咯并吡啶酮类、其制备方法及其作为激酶抑制剂的用途
EP2976335A1 (en) 2013-03-21 2016-01-27 Bayer Pharma Aktiengesellschaft Heteroaryl substituted indazoles
CN105209455A (zh) * 2013-03-21 2015-12-30 拜耳制药股份公司 3-杂芳基取代的吲唑
ES2652305T3 (es) 2013-06-21 2018-02-01 Bayer Pharma Aktiengesellschaft Pirazoles heteroaril sustituidos
EP3010904A1 (en) 2013-06-21 2016-04-27 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
CN105452242A (zh) 2013-06-21 2016-03-30 拜耳制药股份公司 杂芳基取代的吡唑
WO2014202583A1 (en) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
AR097325A1 (es) 2013-08-13 2016-03-09 Gruenenthal Gmbh Pirroles anillados
AR100886A1 (es) 2014-06-17 2016-11-09 Bayer Pharma AG 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
EP3310775B1 (en) 2015-06-17 2020-04-01 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
CN107921286A (zh) 2015-08-05 2018-04-17 拜耳制药股份公司 1h‑吡咯‑3‑胺类化合物
CN108602820A (zh) 2015-12-16 2018-09-28 拜耳制药股份公司 杂-1,5,6,7-四氢-4h-吲哚-4-酮类化合物

Also Published As

Publication number Publication date
US20180016272A1 (en) 2018-01-18
EA032530B1 (ru) 2019-06-28
EA201791692A1 (ru) 2018-01-31
CO2017007663A2 (es) 2017-10-10
BR112017016193A2 (pt) 2018-04-17
AU2016212230A1 (en) 2017-07-20
JP2018503648A (ja) 2018-02-08
DOP2017000176A (es) 2017-08-31
EP3250567A1 (en) 2017-12-06
AU2016212230B2 (en) 2019-09-19
SG11201705908VA (en) 2017-08-30
NI201700096A (es) 2017-10-24
BR112017016193B1 (pt) 2023-02-23
CA2974853C (en) 2023-02-21
KR102544847B1 (ko) 2023-06-16
MX2017009831A (es) 2017-11-02
IL253284B (en) 2020-08-31
IL253284A0 (en) 2017-09-28
TW201639828A (zh) 2016-11-16
TN2017000329A1 (en) 2019-01-16
PE20171240A1 (es) 2017-08-24
UA122221C2 (uk) 2020-10-12
CN107406417A (zh) 2017-11-28
CA2974853A1 (en) 2016-08-04
ZA201705802B (en) 2019-07-31
PH12017501340A1 (en) 2017-12-18
EP3250567B1 (en) 2019-10-30
KR20170106452A (ko) 2017-09-20
JP6704398B2 (ja) 2020-06-03
HK1244804A1 (zh) 2018-08-17
TWI699359B (zh) 2020-07-21
CR20170345A (es) 2017-09-29
WO2016120196A1 (en) 2016-08-04
CL2017001930A1 (es) 2018-03-09
MY182181A (en) 2021-01-18
US10428063B2 (en) 2019-10-01
SV2017005487A (es) 2019-01-17
ECSP17048527A (es) 2017-10-31
CN107406417B (zh) 2020-06-09
UY36544A (es) 2016-08-31
JO3706B1 (ar) 2021-01-31

Similar Documents

Publication Publication Date Title
CU20170094A7 (es) Derivados de 4h-pirrol[3,2-c]piridin-4-0na
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
ECSP18094790A (es) Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
PH12018500718A1 (en) Compounds useful as modulators of trpm8
CL2017002483A1 (es) Compuestos heterocíclicos como inhibidores de lsd1
CL2017003073A1 (es) Inhibidores de tirosina-cinasas
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
CO2017001884A2 (es) Polimorfos de selinexor
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
UY36076A (es) Compuestos útiles como inhibidores de la interacción proteínaproteína pd-1/pd-l1 y cd80/pd-l1, y composiciones farmacéuticas que los contienen.
CU24410B1 (es) Benzimidazol-2-aminas como inhibidores de midh1
CU20170015A7 (es) Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il
CR20200276A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamientos de la hepatitis b (divisional exp. 2015-0059)
CL2014000746A1 (es) Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer.
CR20140071A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
EA201692114A1 (ru) Замещенные дигидроизохинолиноновые соединения
UY36702A (es) Piridinas sustituidas y métodos de uso
CO2017001528A2 (es) Compuestos novedosos de pirimidina sustituidos
CO2017001506A2 (es) Compuestos novedosos de pirimidina sustituidos
ECSP17010482A (es) Novedosas pirimidinas 2,5-sustituidas
DOP2016000211A (es) Pirazinas moduladoras de gpr6
EA201590656A1 (ru) Азаиндолины
EA201791396A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
EA201892188A1 (ru) Соединения пирролотриазина в качестве ингибиторов tam